SUBSCRIBE
SUBSCRIBE

Spinal muscular atrophy

Drug Development
Spinal Muscular Atrophy May Also Affect the Heart, Nationwide Children’s Hospital Study Finds
August 13, 2010
 · 
1 min read
Bookmark and Share
BioMidwest
Study Finds Screening For Spinal Muscular Atrophy Not Cost Effective, Society for Maternal-Fetal Medicine
February 5, 2010
 · 
1 min read
Bookmark and Share
Pharm Country
Drug Candidate For Treating Spinal Muscular Atrophy Identified at Cold Spring Harbor Laboratory
November 9, 2009
 · 
1 min read
Bookmark and Share
BioMidwest
Possible Treatment For Spinal Muscular Atrophy, Iowa State University Study
July 31, 2009
 · 
1 min read
BioMidwest
University of Wisconsin-Madison Scientists Find Potent New Weapon To Fight Spinal Muscular Atrophy
December 22, 2008
 · 
1 min read
BioMidwest
National Institutes of Health (NIH): Treatment Extends Survival In Mouse Model Of Spinal Muscular Atrophy
February 23, 2007
 · 
1 min read
Load More
PRESS RELEASES
Press Releases
FDA approves Roche’s Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA)
February 13, 2025
 · 
7 min read
Press Releases
FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)
February 13, 2025
 · 
9 min read
Press Releases
FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA
January 23, 2025
 · 
7 min read
Press Releases
Majority of Children With Spinal Muscular Atrophy (SMA) Treated With Genentech’s Evrysdi Are Able to Sit, Stand and Walk Independently, Two-Year Data Demonstrate
October 14, 2024
 · 
10 min read
Press Releases
Majority of children with spinal muscular atrophy (SMA) treated with Roche’s Evrysdi are able to sit, stand and walk independently, two-year data demonstrate
October 14, 2024
 · 
8 min read
Press Releases
Spinal Muscular Atrophy Market Size to Reach US$ 13.0 Billion by 2034, Impelled by Increased Popularity of Gene Therapy
July 17, 2024
 · 
12 min read
Biotech Bay
Five-year Data for Genentech’s Evrysdi Show the Majority of Treated Children With a Severe Form of Spinal Muscular Atrophy (SMA) Achieved or Maintained the Ability to Sit, Stand or Walk
June 7, 2024
 · 
9 min read
Policy
Majority of Newborn Babies With Spinal Muscular Atrophy (SMA) Treated With Genentech’s Evrysdi Able to Sit Independently After 1 Year of Treatment
October 4, 2023
 · 
9 min read
Pharm Country
Biohaven’s Taldefgrobep Alfa Receives EU Orphan Drug Designation for Spinal Muscular Atrophy
July 31, 2023
 · 
6 min read
Biotech Bay
Four-Year Follow-Up Data for Genentech’s Evrysdi Show Continued Increase in Number of Children With a Severe Form of Spinal Muscular Atrophy (SMA) Able to Sit, Stand and Walk
June 30, 2023
 · 
9 min read
FDA
Biohaven’s Taldefgrobep Alfa Receives FDA Fast Track Designation for Spinal Muscular Atrophy
February 21, 2023
 · 
5 min read
FDA
PerkinElmer Announces its EONIS SCID-SMA Kit is First to Receive Marketing Authorization by U.S. FDA for SMA Screening in Newborns
November 14, 2022
 · 
3 min read
Spinal Muscular Atrophy Treatment Market Size to Hit USD 18.9 BN by 2030
November 7, 2022
 · 
9 min read
Biotech Bay
Positive New Data for Genentech’s Evrysdi in Largest Trial Ever Undertaken in Patients With Previously-Treated Spinal Muscular Atrophy (SMA)
October 12, 2022
 · 
10 min read
Drug Development
Biophytis Presents Preclinical Efficacy Data for Sarconeos (BIO101) in Spinal Muscular Atrophy (SMA), a Rare Neuromuscular Disease
June 16, 2022
 · 
4 min read
Genetown
New Data Presented at Cure SMA Reveal Residual Unmet Needs in Young SMA Patients Treated With Gene Therapy and Suggest Further Potential of Using SPINRAZA® (nusinersen)
June 15, 2022
 · 
10 min read
Policy
FDA Approves Label Extension for Evrysdi® for Infants with Spinal Muscular Atrophy Under 2 Months Old
May 31, 2022
 · 
8 min read
Policy
FDA Approves Genentech’s Evrysdi (risdiplam) for Use in Babies Under Two Months With Spinal Muscular Atrophy (SMA)
May 31, 2022
 · 
9 min read
Biotech Bay
New Data for Genentech’s Evrysdi (risdiplam) Demonstrate Long-Term Efficacy and Safety in a Broad Population of People With Spinal Muscular Atrophy (SMA)
March 16, 2022
 · 
10 min read
Policy
FDA Grants Evrysdi® Priority Review Based on Results From Treating Pre-Symptomatic Infants with Spinal Muscular Atrophy
January 25, 2022
 · 
8 min read
Load More